logo
    • Magazine
    • Membership
    • Donate
  • Racial Justice
  • Economic Justice
    • Collections
  • Climate Justice
  • Health Justice
  • Leadership
  • CONTENT TYPES
  • Subscribe
  • Webinars
    • Upcoming Webinars
    • Complimentary Webinars
    • Premium On-Demand Webinars
  • Membership
  • Submissions

The 21st Century Cures Act: Great Response to What Ails Pharmaceutical Giants

Sheela Nimishakavi
December 9, 2016
Share
Tweet
Share
Email
Print

December 8, 2016; New York Times

While most of us have been staring at our screens awaiting the latest Trump administration appointment (or avoiding politics completely), the U.S. Senate and House of Representatives passed what can be considered an extraordinary piece of bipartisan legislation. Dubbed the 21st Century Cures Act, this bill approves $4.8 billion in spending over the next ten years for new research conducted by the National Institutes of Health to address cancer research, mapping the brain, genetic data collection, and prescription drug abuse.

Support for this bill has been overwhelming, with President Obama saying, “We are now one step closer to ending cancer as we know it, unlocking cures for diseases like Alzheimer’s and helping people seeking treatment for opioid addiction finally get the help they need. This bill will make a difference, and I look forward to signing it as soon as it reaches my desk.” He will likely get the opportunity soon, as the legislation passed in the House 392-26 and in the Senate 94-5.

Sign up for our free newsletters

Subscribe to NPQ's newsletters to have our top stories delivered directly to your inbox.

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

With the promise of cures for some of the most prevalent diseases, it may seem surprising that anyone voted against the bill. But a closer look at what else has been promised with the 21st Century Cures Act reveals a conflict. Not only will the NIH be able to research and develop cures, some of which have already been researched and completed successfully by private companies, pharmaceutical and medical device companies will also be able to fast track treatments through the U.S. Food and Drug Administration approval process. Of particular note, the Act will allow the FDA to consider “clinical experience” data instead of relying on clinical trials, allow companies to request speedy approval of medicines and technologies for life-threatening or rare diseases, and expedite manufacturing to speed up patient access to new treatments.

It would appear that getting newer and better treatments to patients quicker would be ideal. However, experts question whether this Act also raises patient risk. President of the National Center for Health Research Diana Zuckerman says, “The FDA over all these decades has developed a way to know what products work and which ones don’t, but in the last decade they have been pushed to lower those standards. With this bill, they’d lower them even more.”

The advantage for Big Pharma and medical device companies is readily apparent. It’s no coincidence that over a thousand lobbyists for the sector helped push this bill along. What has yet to be determined is whether the benefit to patients will justify the benefits for the pharmaceutical and medical device industry. The Act does not include a provision regarding the cost to the patient for treatments; as such, it is possible that we are doomed to repeat what happened with anti-retroviral therapy—treatment that is highly effective yet prohibitively expensive—and patients would not benefit much at all.—Sheela Nimishakavi

Share
Tweet
Share
Email
Print
About the author
Sheela Nimishakavi

Sheela Nimishakavi is a nonprofit finance and operations professional with a passion for creating socially just and inclusive communities. She has held senior management positions at several community based organizations addressing access to healthcare and services for persons with disabilities, currently serving as the Director of Operations of the Brain Injury Association of Virginia. After working in the nonprofit field for over a decade and seeing many organizations struggle with the administrative requirements of running a nonprofit, Sheela founded ThirdSuite, a consulting firm that offers nonprofit administrative services and trainings to help organizations increase their capacity and further their mission. Sheela received an MA/MPH in Health Policy and Management from Boston University School of Public Health, and a BS in Neurobiology, Physiology and Behavior from the University of California, Davis. She currently serves on the boards of the Central Virginia Grant Professionals Association and Empowering People for Inclusive Communities.

More about: LegislationNonprofit NewsPolicy

Become a member

Support independent journalism and knowledge creation for civil society. Become a member of Nonprofit Quarterly.

Members receive unlimited access to our archived and upcoming digital content. NPQ is the leading journal in the nonprofit sector written by social change experts. Gain access to our exclusive library of online courses led by thought leaders and educators providing contextualized information to help nonprofit practitioners make sense of changing conditions and improve infra-structure in their organizations.

Join Today
logo logo logo logo logo
See comments

Spring-2023-sidebar-subscribe
You might also like
The Nonprofit Sector and Social Change: A Conversation between Cyndi Suarez and Claire Dunning
Claire Dunning and Cyndi Suarez
Nonprofits as Battlegrounds for Democracy
Cyndi Suarez
Cancelling Student Debt Is Necessary for Racial Justice
Kitana Ananda
To Save Legal Aid, Expand Public Service Loan Forgiveness
Zoë Polk
No Justice, No Peace of Mind and Body: The Health Impacts of Housing Insecurity for Black Women
Jhumpa Bhattacharya, Maile Chand and Andrea Flynn
The Human Impact of the Global Refugee Crisis Must Be Understood—And Acted Upon
Anmol Irfan

NPQ Webinars

April 27th, 2 pm ET

Liberatory Decision-Making

How to Facilitate and Engage in Healthy Decision-making Processes

Register Now
You might also like
The book "Nonprofit Neighborhoods" leaning against a wall
The Nonprofit Sector and Social Change: A Conversation...
Claire Dunning and Cyndi Suarez
Nonprofits as Battlegrounds for Democracy
Cyndi Suarez
Cancelling Student Debt Is Necessary for Racial Justice
Kitana Ananda

Like what you see?

Subscribe to the NPQ newsletter to have our top stories delivered directly to your inbox.

See our newsletters

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

NPQ-Spring-2023-cover

Independent & in your mailbox.

Subscribe today and get a full year of NPQ for just $59.

subscribe
  • About
  • Contact
  • Advertise
  • Copyright
  • Careers

We are using cookies to give you the best experience on our website.

 

Non Profit News | Nonprofit Quarterly
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.